 |
|
Brain Biopsy in Patients With Acquired Immunodeficiency Syndrome
Diagnostic Value, Clinical Performance, and Survival Time
Mathias W. Hornef, MD;
Anne Iten, MD;
Philippe Maeder, MD;
Jean-Guy Villemure, MD;
Luca Regli, MD
Arch Intern Med. 1999;159:2590-2596.
Background Despite extensive discussion in recent years, brain biopsy in patients positive for human immunodeficiency virus who manifest cerebral mass lesions remains an ill-defined step in management.
Methods Prebiopsy data of 26 human immunodeficiency virus–positive patients with cerebral mass lesions who underwent computed tomography–guided stereotactic brain biopsy (SBB) were reviewed by a specialist in infectious diseases and by a neuroradiologist to establish a clinical diagnosis and a treatment plan for each patient. The postbiopsy diagnosis was compared with the prebiopsy diagnosis. Long-term patient outcome after SBB was recorded by means of a clinical performance scale to estimate its impact on life expectancy and clinical performance.
Results The SBB was diagnostic in 25 patients (96%). Potentially treatable disease was diagnosed in 21 patients (81%), and specific therapy was initiated in 17 patients (65%); 10 patients (39%) were able to complete therapy. The SBB corroborated the clinical diagnosis in 13 (52%) of 25 patients. The group with identical clinical and biopsy-proved diagnoses showed significantly better response to therapy (P=.02), clinical performance (P=.04), and survival after biopsy (P=.01), as compared with the group with different clinical and biopsy-proved diagnosis, although no significant difference was found for the degree of immunosuppression. Only completion of the treatment plan increased life expectancy significantly (P=.008).
Conclusions These data show that in human immunodeficiency virus–positive patients with brain mass lesions, SBB has a high diagnostic yield. A subgroup of patients will benefit from specific therapy guided by the SBB result. The procedure should, however, be strictly limited to patients able to tolerate specific therapy.
From the Departments of Neurosurgery (Drs Hornef, Villemure, and Regli), Internal Medicine (Division of Infectious Diseases) (Dr Iten), and Radiology (Dr Maeder), Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Dr Hornef is now with the Max von Pettenkofer-Institut, Ludwig-Maximilian Universität München, Munich, Germany.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 1999;159(21):2605-2606.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
How Valuable Is Brain Biopsy in HIV-Infected Patients?
JWatch Neurology 2000;2000:15-15.
FULL TEXT
Utility of Brain Biopsy
AIDS Clin Care 2000;2000:9-9.
FULL TEXT
|
